Analysts Are Positive On Intercept Pharmaceuticals, Inc. Following Quarterly Earnings And Pipeline Update
May 12, 2015 at 08:45 AM EDT
Intercept Pharmaceuticals is developing obeticholic acid, or OCA, for patients with the liver disease PBC.
